Research into Hepatitis B seroprevalence among children aged 1-18 years in Usak province and comparison with seroprevalence in other provinces and Turkey

Hepatitis B (HBV) infection is a significant health problem around the world. Turkey is a country with moderate endemicity. This study aims to investigate the seroprevalence of HBV and anti-Hbs seropositivity among children and young adults aged 1 to 18 years living in Usak province of Turkey. This is a retrospective review of 720 children, 394 boys and 326 girls, aged 1 to 18 years who were admitted to Usak Private Medical Park Hospital for any reason between January 2017 and December 2018. Anti-Hbs seropositivity was identified in 471 children including 63% of the boys (249/394) and 68% of the girls (222/326) in the study cohort. Only one case of HbsAg positivity (0.001%) was specified among 720 children. Anti-Hbs seropositivity was 83% in Group 1 (82/99), 61% in Group 2 (62/101), 55% in Group 3 (51/92), 56% in Group 4 (43/77) and 66% in Group 5 (233/350). To the best of our knowledge, this hospital-based cross-sectional study is the first clinical research of the 1-18-year age group for HbsAg seroprevalence and anti-Hbs seropositivity in Usak province. When compared with other provinces and Turkey in general, HbsAg seropositivity rate is relatively low in this study.

PDF

___

1. Global Hepatitis Report, 2017. WHO. http://www.who.int/hepatitis/ publications/global-hepatitis-report2017/en/ access date: 10.10.2019

2. Tabak F. Enfeksiyon Hastalıkları Kitabı. 2. Baskı. Nobel tıp Kitabevleri. Istanbul 2003;233-42.

3. Venters C, Graham W, Cassidy W. Recombivax-HB: perspectives past, present and future. Expert Rev Vaccines. 2004;3:119-29.

4. Leuridan E, Van Damme P. Hepatitis B and the need for a boosterdose. Clin Infect Dis. 2011;53:68-75.

5. T.C. Sağlık Bakanlığı Türkiye Viral Hepatit Önleme Ve Kontrol Programı 2018-2023. Sağlık Bakanlığı Yayın No: 1102, Ankara, 2018;4-8.

6. Tozun N, Ozdogan O, Cakaloglu Y, et al. Seroprevalence of hepatitis B and C virüs infections and risk factors in Turkey: a fieldwork TURHEP study. Clin Microbiol Infect. 2015;21:1020-6.

7. Wasley A, Kruszon Moran D, Kuhnert W, et al. The Prevalence of Hepatitis B VirusInfection in the United States in the Era of Vaccination. The J. Infect Dis. 2010;202:192-201

8. Kösecik M, Emiroğlu H, Tatlı M, ve ark. Şanlıurfa yöresinde çocuklarda asemptomatik hepatitis B virüs taşıyıcılığı prevalansı. Türk Pediatri Ars. 1998;2:106-9.

9. Zeyrek CD, Zeyrek FY, İşcan A, ve ark. Şanlıurfa’da çocuklarda hepatit A, B, C seroprevalansı. Viral Hepat J. 2002;8:467-70.

10. Nalbantoğlu B, Nalbantoğlu A, Külcü NU, ve ark. Dokuz Ay - 8 Yaş Arası Çocuklarda Hepatit B Seroprevalansı ve Aşılanma Durumları. Çocuk Dergisi. 2010;10:116-21.

11. Çiçek AÇ, Özkasap S, Dereci S, ve ark. Rize ilinde çocuk hastalarda hepatit A, B ve C seroprevalansı. Viral Hepat J. 2012;18:102-6.

12. Kaya A, Erbey MF, Okur M, et al. Hepatitis B virüs Seropositivity and Vaccination for children aged 0-18 in the Van region. J Pediatr Inf. 2011;5:132-5.

13. Altan H, Demirtaş S, Taş D, ve ark. Ankara’da bir devlet hastanesine başvuran çocuklarda hepatit B seroprevalansının belirlenmesi. Ankara Med J. 2017;17:1-8.

14. Doğan E , Sevinç E , Kuru C. Seroprevalence of HAV, HBV, and HCV in pediatric patients in Karabük province. Akademik Gastroenteroloji Dergisi. 2017;16:97-100.

15. Duran F, Kaya A , Zararsız A, ve ark. Seroprevalance of Hepatitis B, Hepatitis C and Hepatitis D in children between 0-18 years of age attenting to our hospital. J Pediatr Inf. 2017;11:1-6.

16. Süleyman A, Gökçay G, Badur S, ve ark. Süt çocukluğunda Hepatit B aşısı uygulanan çocuklarda serolojik durumun değerlendirilmesi. Mikrobiyoloji Bülteni. 2012;46:47-56.

17. Tosun SY, Eser E, Sır E, ve ark. Manisa ili Muradiye Sağlık Ocağı merkez bölgesinde 1998 yılında hepatit B aşılama programına alınan cocuklarda dört yıl sonraki aşı koruyuculuk düzeyinin araştırılması. MN Klinik Bilimler & Doktor. 2003;9:459-66.

18. Erol M, Velipaşaoğlu S, Uğuz A, ve ark. Türk Bebeklerinde Hepatit B aşısının Etkinliği. Türk Pediatri Arşivi. 2000;35:252-5.

19. McMahon BJ, Dentinger CM, Bruden D, et al. Antibody level and protection after hepatitis B vaccine: results of a 22-year follow-up study and response to a boosterdose. J Infect Dis. 2009;200:1390–6.